Table 2.

Crude and adjusted clinical outcomes

	Both ECG-based and echo-based LVH Number of patients with event/N of patients at risk (cumulative 3-year incidence(%))	Only echo-based LVH Number of patients with event/N of patients at risk (cumulative 3-year incidence(%))	Only ECG-based LVH Number of patients with event/N of patients at risk (cumulative 3-year incidence(%))	No LVH Number of patients with event/N of patients at risk (cumulative 3-year incidence(%))	Variables	Unadjusted		Adjusted
						HR (95% CI)	P value	HR (95% CI)	P value
Primary endpoint
A composite of all-cause death or MACE	34/131 (32.0)	45/156 (33.8)	65/409 (19.2)	307/2516 (15.7)	Both ECG- and echo-based LVH	2.33 (1.70 to 3.19)	<0.001	1.63 (1.16 to 2.28)	0.005
					Only echo-based LVH	2.21 (1.64 to 2.97)	<0.001	1.68 (1.23 to 2.30)	0.001
					Only ECG-based LVH	1.12 (0.87 to 1.44)	0.38	1.09 (0.85 to 1.41)	0.49
					No LVH	1 (reference)		1 (reference)
Secondary endpoints
All-cause death	16/131 (15.8)	21/156 (15.9)	36/409 (10.7)	203/2516 (10.4)	Both ECG-based and echo-based LVH	1.59 (1.03 to 2.45)	0.04	1.43 (0.90 to 2.27)	0.13
					Only echo-based LVH	1.39 (0.91 to 2.13)	0.13	1.22 (0.78 to 1.89)	0.39
					Only ECG-based LVH	0.93 (0.67 to 1.29)	0.66	0.94 (0.68 to 1.30)	0.71
					No LVH	1 (reference)		1 (reference)
MACE	23/131 (22.5)	26/156 (21.8)	38/409 (11.8)	139/2516 (7.5)	Both ECG-based and echo-based LVH	3.48 (2.35 to 5.16)	<0.001	1.91 (1.25 to 2.91)	0.003
					Only echo-based LVH	2.89 (1.95 to 4.28)	<0.001	1.86 (1.23 to 2.81)	0.003
					Only ECG-based LVH	1.45 (1.04 to 2.03)	0.03	1.38 (0.98 to 1.93)	0.06
					No LVH	1 (reference)		1 (reference)

LVH, left ventricular hypertrophy; MACE, major adverse cardiovascular events.